Section 5 · Pre-Market Prep
Evaluating a Catalyst
Strong catalyst = conviction. Weak catalyst = trap.
Not All Catalysts Are Created Equal
A 40% pre-market gap on a vague press release and a 40% pre-market gap on an FDA drug approval look identical on a price chart. They are completely different trades. The catalyst is the foundation of every momentum trade — without a strong catalyst, there is no institutional conviction, no sustained buying pressure, and no follow-through. Catalyst evaluation is the single most important skill in pre-market preparation. You need to ask: Does this catalyst change the company's future cash flows? Does it create urgency for institutional investors to revalue their positions? Is it binary (yes/no) or vague (maybe/eventually)? Binary catalysts — FDA decisions, quarterly earnings, acquisition announcements — force immediate repricing. Vague catalysts — partnerships without revenue terms, speculative social media posts, analyst reiterations — create noise moves that reverse quickly. The practical test: if you had to explain the catalyst to a 10-year-old, would it be clearly good or bad news? "The FDA approved their cancer drug — they can now sell it" is a clear catalyst. "The company entered into a strategic collaboration to explore synergistic opportunities" is noise. When in doubt, pass on the trade.
3 things to know
FDA drug approvals are considered the highest-quality catalyst in biotech — binary, definitive, and often transformational for small-cap companies.
Secondary offerings (companies issuing new shares) are almost always negative catalysts — they dilute existing shareholders.
Acquisition announcements typically create sustained buying across the entire sector, not just the target company.
Dive Deeper
Myth
A big gap always means a strong catalyst.
Reality
Gap size reflects pre-market buying pressure, not catalyst quality. Retail FOMO can create a 40% gap on a vague PR that reverses 80% within the first hour of trading.
Myth
Social media hype is a valid catalyst for momentum trades.
Reality
Unverified social media activity is one of the most dangerous false catalysts. Without a regulatory filing, earnings report, or press release, the move has no institutional support and is highly prone to reversal.
Myth
Any news is better than no news for a long trade.
Reality
Certain news is actively negative. Secondary offerings, clinical trial failures, and regulatory setbacks create gaps that collapse. Always identify the direction of the catalyst, not just its existence.
Key vocabulary — tap each card
Practice
Strong vs. Weak Catalysts
✅ Pros
- FDA drug approval (PDUFA decision)
- Earnings beat >15% above consensus
- Acquisition or merger announcement
- Short squeeze on high short interest float
- Positive Phase 3 clinical trial data
❌ Cons
- Vague press release with no revenue figures
- Secondary offering (new share issuance)
- Analyst price target reiteration
- Sympathy gap from sector peer news
- Unconfirmed social media rumor
Did you know?
Stocks gapping on vague press releases — those without specific financial figures, regulatory approvals, or binding agreements — reverse at the open more than 65% of the time. Many experienced traders have a rule: if you can't explain the catalyst in one clear sentence, you don't trade it.